Tittes, Julia http://orcid.org/0000-0003-0844-3626
Brell, Jennifer http://orcid.org/0000-0001-5191-9031
Fritz, Pia http://orcid.org/0000-0003-4998-5763
Jonak, Constanze http://orcid.org/0000-0002-2347-436X
Stary, Georg http://orcid.org/0000-0003-1746-4250
Ressler, Julia M. http://orcid.org/0000-0001-8602-0878
Künig, Sarojinidevi http://orcid.org/0000-0002-2385-7483
Weninger, Wolfgang http://orcid.org/0000-0003-3133-8699
Stöckl, Johannes http://orcid.org/0000-0002-3304-6975
Funding for this research was provided by:
Lilly Deutschland (project no. I1F-OE-O001)
Article History
Received: 17 November 2023
Accepted: 8 February 2024
First Online: 8 March 2024
Declarations
:
: Other than that mentioned above, Julia Tittes reports consulting fees from Lilly, speaker honoraria from Lilly and Novartis, all outside the submitted work, as well as travel support from Almirall, AbbVie and Bristol-Myers Squibb through institution. Julia M. Ressler received speaker honoraria from Bristol-Myers Squibb, Roche, Amgen and Novartis and travel support by Sanofi, Roche and Bristol-Myers Squibb through institution. All other authors declare no conflicts of interest (COI). The corresponding author, Julia Tittes, has changed her affiliation after the completion of the manuscript. Her new affiliation is the Institute for Clinical Pathology and Molecular Pathology at the University Clinic St.Pölten-Lilienfeld (Karl Landsteiner University).
: The study was approved in accordance with the Helsinki Declaration of 1964 and its later amendments by the ethics committee of the Medical University of Vienna (ECS 1642/2017) on the 25th of September 2017 and followed national law and ethical principles in research. It required voluntary participation of patients and healthy controls with written informed consent. Additionally, all patients gave written informed consent to the release of clinical images captured.